SAN ANTONIO (EGMN) - The bone loss associated with aromatase inhibitor therapy may be manageable via bone density monitoring and the use of oral risedronate at a dose licenced for osteoporosis, according to the interim findings of two ongoing clinical trials presented at the annual San Antonio Breast Cancer Symposium.Dr. Shalini Singh provided the 1-year results of the bone substudy of the International Breast Cancer Prevention Study (IBIS-II), in which a planned 6,000 postmenopausal women at high...